Q BioMed Inc. (QBIO)
OTCQB OTCQB Primary Summary
QBIO Chart
Q BioMed Inc. Dividends
Q BioMed Inc. Earnings
| 26 Aug 2024 Date | | - Cons. EPS | - EPS |
| 23 Aug 2024 Date | | - Cons. EPS | - EPS |
| 21 Aug 2024 Date | | - Cons. EPS | - EPS |
| 19 Aug 2024 Date | | - Cons. EPS | - EPS |
| 15 Aug 2024 Date | | - Cons. EPS | - EPS |
| 26 Aug 2024 Date | | - Cons. EPS | - EPS |
| 23 Aug 2024 Date | | - Cons. EPS | - EPS |
| 21 Aug 2024 Date | | - Cons. EPS | - EPS |
| 19 Aug 2024 Date | | - Cons. EPS | - EPS |
| 15 Aug 2024 Date | | - Cons. EPS | - EPS |
Q BioMed Inc. (QBIO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Q BioMed Inc. ever had a stock split?
Q BioMed Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Denis D. Corin CEO | OTCQB Exchange | US74736N1054 ISIN |
| US Country | - Employees | - Last Dividend | 7 Aug 2015 Last Split | - IPO Date |
Overview
Q BioMed Inc. is a biomedical acceleration and development company that specializes in licensing, acquiring, and providing resources to life sciences and healthcare entities. Initially named ISMO Tech Solutions, Inc., the company underwent a rebranding to Q BioMed Inc. in July 2015. Founded in 2013 and headquartered in New York, New York, the organization aims to facilitate the advancement of therapeutic and diagnostic products from development stages through to commercialization. Q BioMed Inc. has forged a strategic partnership with Mannin Research Inc. to pioneer the development of therapeutic drugs aimed at addressing a diverse array of medical conditions, including acute respiratory distress syndrome, glaucoma, kidney diseases, and more.
Products and Services
Q BioMed Inc. offers a comprehensive portfolio of products and services aimed at addressing critical medical needs. These include:
- Strontium Chloride Sr-89 and Metastron: A radiopharmaceutical therapeutic duo used in the treatment of metastatic bone cancer pain, providing relief to patients suffering from this severe condition.
- Man-01: A cutting-edge treatment under development for primary open angle glaucoma, showcasing Q BioMed Inc.'s commitment to combating major eye diseases with innovative solutions.
- QBM-001: Tailored for the rare pediatric non-verbal autism spectrum disorder, this treatment represents the company's focus on addressing underserved medical areas, especially within pediatric care.
- Uttroside-B: A novel chemotherapeutic agent for liver cancer, highlighting Q BioMed Inc.'s contribution to the fight against cancer with promising new treatments.
Contact Information
